Intestinal barrier and permeability in health, obesity and NAFLD

P Portincasa, L Bonfrate, M Khalil, MD Angelis… - Biomedicines, 2021 - mdpi.com
The largest surface of the human body exposed to the external environment is the gut. At this
level, the intestinal barrier includes luminal microbes, the mucin layer, gastrointestinal …

Role of gut microbiota on onset and progression of microvascular complications of type 2 diabetes (T2DM)

DM Tanase, EM Gosav, E Neculae, CF Costea… - Nutrients, 2020 - mdpi.com
Type 2 diabetes mellitus (T2DM) remains one of the most problematic and economic
consumer disorders worldwide, with growing prevalence and incidence. Over the last years …

Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)

MS Kuchay, S Krishan, SK Mishra, NS Choudhary… - Diabetologia, 2020 - Springer
Aims/hypothesis Liraglutide, a daily injectable glucagon-like peptide-1 receptor (GLP-1r)
agonist, has been shown to reduce liver fat content (LFC) in humans. Data regarding the …

Gut microbiota in the pathogenesis and therapeutic approaches of diabetes

L Crudele, RM Gadaleta, M Cariello, A Moschetta - EBioMedicine, 2023 - thelancet.com
The gut–liver axis plays a prominent role in the pathogenesis and therapy of metabolic
diseases such as diabetes. The intestinal specific origin of several hormones that guide both …

Liver steatosis, gut-liver axis, microbiome and environmental factors. A never-ending bidirectional cross-talk

A Di Ciaula, J Baj, G Garruti, G Celano… - Journal of clinical …, 2020 - mdpi.com
The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing worldwide and
parallels comorbidities such as obesity, metabolic syndrome, dyslipidemia, and diabetes …

Nonalcoholic fatty liver disease: modulating gut microbiota to improve severity?

J Aron-Wisnewsky, MV Warmbrunn, M Nieuwdorp… - Gastroenterology, 2020 - Elsevier
Gut microbiota plays a role in the pathophysiology of metabolic diseases, which include
nonalcoholic fatty liver diseases, through the gut–liver axis. To date, clinical guidelines …

Akkermansia muciniphila as a Next-Generation Probiotic in Modulating Human Metabolic Homeostasis and Disease Progression: A Role Mediated by Gut–Liver …

H Jian, Y Liu, X Wang, X Dong, X Zou - International Journal of Molecular …, 2023 - mdpi.com
Appreciation of the importance of Akkermansia muciniphila is growing, and it is becoming
increasingly relevant to identify preventive and/or therapeutic solutions targeting gut–liver …

Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives

H Hu, A Lin, M Kong, X Yao, M Yin, H Xia, J Ma… - Journal of …, 2020 - Springer
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of dysregulated lipid
and glucose metabolism, which is often associated with obesity, dyslipidemia and insulin …

The role of gut–liver axis in gut microbiome dysbiosis associated NAFLD and NAFLD-HCC

Q Song, X Zhang - Biomedicines, 2022 - mdpi.com
Nonalcoholic fatty liver disease (NAFLD) is considered as one of the most prevalent chronic
liver diseases worldwide due to the rapidly rising prevalence of obesity and metabolic …

[HTML][HTML] Gut microbes in metabolic disturbances. Promising role for therapeutic manipulations?

P Portincasa, M Khalil, A Graziani, G Frühbeck… - European Journal of …, 2024 - Elsevier
The prevalence of overweight, obesity, type 2 diabetes, metabolic syndrome and steatotic
liver disease is rapidly increasing worldwide with a huge economic burden in terms of …